Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback